Gene therapy for hemophilia has made remarkable progress over the past two decades, culminating in the approval of the first AAV-based treatments for both hemophilia A and B. Current evidence demonstrates that the durability of FIX expression in hemophilia B is superior and more consistent than FVIII expression in hemophilia A, which continues to decline over time. This evidence concerns the gene F8 and hemophilia A.